TABLE 4.

Comparison of clinical characteristics and laboratory results between vaccinated and non-vaccinated patients.

	Vaccinated (n = 143)	Non-vaccinated (n = 37)	P-value
Age (IQR)	44 ± 15.7	52 ± 21.47	0.006
Male, n (%)	89 (62.2)	24 (64.9)	0.85
With underlying disease, n (%)	32 (22.4)	21 (56.8)	<0.001
Symptomatic at initial onset, n (%)	94 (65.7)	22 (59.5)	1
Symptomatic at re-positive, n (%)	49 (34.3)	15(40.5)	0.564
Total disease duration (days)	34 (28, 43)	37.5 (32, 43.75)	0.052
COVNAT negative to re-positive duration, IQR (days)	12 (8, 17.75)	12 (10, 19)	0.335
Initial onset to COVNAT negative duration, IQR (days)	11 (8, 16)	13 (7, 19)	0.442
Re-positive to COVNAT negative duration, IQR (days)	6 (3, 11)	6 (3.25, 12.75)	0.345
CoV O gene levels at re-positive time, mean ± SD (Ct)	32.65 ± 4.54	31.61 ± 4.15	0.214
CoV N gene levels at re-positive time, mean ± SD (Ct)	31.62 ± 4.43	30.28 ± 4.52	0.157
Lowest CoV O gene levels during re-positive period, mean ± SD (Ct)	29.36 ± 5.4	26.89 ± 4.8	0.02
Lowest CoV N gene levels during re-positive period, mean ± SD (Ct)	27.9 ± 5.11	26.36 ± 4.89	0.119
Anti-CoV IgG levels at re-positive time, IQR (AU/ml)	79.96 (36.8, 160.07)	1.09 (0, 4.99)	<0.001
Patient with elevated anti-CoV IgG, n (%)	140 (97.9)	20 (54.1)	<0.001
Anti-CoV IgM levels at re-positive time, IQR (AU/ml)	0 (0, 0.486)	0 (0, 0.182)	0.239
Patient with elevated anti-CoV IgM, n (%)	22 (15.4)	2 (5.4)	0.173

CoV, coronavirus; COVID-19, coronavirus disease 2019; COVNAT, coronavirus nucleic acid test. Differences in continuous variables were analyzed using the independent sample T-test or Mann–Whitney U test. Differences in categorical variables were calculated using Fisher’s exact or the Chi-square test as appropriate. P-values indicate differences between mild case and asymptomatic case groups. P < 0.05 was considered statistically significant.